Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

May Shawi

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.
Plos One|August 8, 2013
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytesMay Shawi, Tsz Wai Chu, Veronica Martinez-Marignac, et al.
RMD Open|March 31, 2023
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsAPascal Richette, Marijn Vis, Sarah Ohrndorf, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
RMD Open|March 26, 2024
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled studyLaura C Coates, Laure Gossec, Miriam Zimmermann, et al.
Clinical Rheumatology|June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 studyChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
ACR Open Rheumatology|February 10, 2023
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 StudyChristopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
ACR Open Rheumatology|October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled StudyPhilip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.
Plos One|August 8, 2013
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytesMay Shawi, Tsz Wai Chu, Veronica Martinez-Marignac, et al.
RMD Open|March 31, 2023
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsAPascal Richette, Marijn Vis, Sarah Ohrndorf, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
RMD Open|March 26, 2024
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled studyLaura C Coates, Laure Gossec, Miriam Zimmermann, et al.
Clinical Rheumatology|June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 studyChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
ACR Open Rheumatology|February 10, 2023
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 StudyChristopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
ACR Open Rheumatology|October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled StudyPhilip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Pageof 5